Biotin-conjugated PEGylated porphyrin self-assembled nanoparticles co-targeting mitochondria and lysosomes for advanced chemo-photodynamic combination therapy

2019 ◽  
Vol 7 (1) ◽  
pp. 65-79 ◽  
Author(s):  
Baskaran Purushothaman ◽  
Jinhyeok Choi ◽  
Solji Park ◽  
Jeongmin Lee ◽  
Annie Agnes Suganya Samson ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Synergistic Effects ◽  
Self Assembled

In this study, the chemo-drug doxorubicin (DOX) was successfully encapsulated in PEG–biotin conjugated porphyrin SANs (DOX@TPP–PEG–biotin) and had synergistic effects after PDT action.

Landscape of Combination Therapy – Which Way Forward? Proceedings of the Satellite Symposium Held at the ESH European Meeting on Hypertension and Cardiovascular Protection, 27 April 2012, London

2012 ◽  
Vol 8 (3) ◽  
pp. 192
Author(s):  
Patricia Fonseca ◽  
Anna F Dominiczak ◽  
Stephen Harrap ◽  
◽  
◽  
...  
Keyword(s):  
Blood Pressure ◽  
High Risk ◽  
Combination Therapy ◽  
Enzyme Inhibitor ◽  
Synergistic Effects ◽  
Term Treatment ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Hypertensive Patients ◽  
Long Term Treatment

Early combination therapy is more effective for hypertension control in high-risk patients than monotherapy, and current guidelines recommend the use of either an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) for first-line therapy in patients younger than 55 years. Recent evidence shows that ACEIs reduce mortality, whereas ARBs show no apparent benefit despite their blood pressure lowering action. However, it is important to consider which blood pressure parameters should be targeted given that different drugs have distinct effects on key parameters. Remarkably, a high percentage of hypertensive patients whose treatment has brought these parameters within target ranges still remain at high risk of cardiovascular disease due to additional risk factors. Combination therapy with synergistic effects on blood pressure and metabolic control should thus be considered for the long-term treatment of hypertensive patients with co-morbid conditions.

scholarly journals Self-assembled albumin nanoparticles for combination therapy in prostate cancer

2017 ◽  
Vol Volume 12 ◽  
pp. 7777-7787 ◽  
Author(s):  
Huibo Lian ◽  
Jinhui Wu ◽  
Yiqiao Hu ◽  
Hongqian Guo
Keyword(s):  
Prostate Cancer ◽  
Combination Therapy ◽  
Albumin Nanoparticles ◽  
Self Assembled

Toxic Reactive Oxygen Species Enhanced Synergistic Combination Therapy by Self-Assembled Metal-Phenolic Network Nanoparticles

2018 ◽  
Vol 30 (8) ◽  
pp. 1704877 ◽  
Author(s):  
Yunlu Dai ◽  
Zhen Yang ◽  
Siyuan Cheng ◽  
Zhongliang Wang ◽  
Ruili Zhang ◽  
...  
Keyword(s):  
Reactive Oxygen Species ◽  
Combination Therapy ◽  
Reactive Oxygen ◽  
Oxygen Species ◽  
Synergistic Combination ◽  
Self Assembled

CTNI-52. RETROSPECTIVE ANALYSIS OF USING RADIOTHERAPY WITH CONCURRENT TEMOZOLOMIDE AND TUMOR TREATING FIELDS FOR CHINESE PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi72-vi72
Author(s):  
Yang Wang ◽  
Jingsong Wu ◽  
Zhiyong Qin ◽  
Enmin Wang ◽  
Yu Yao ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Adverse Reactions ◽  
Treatment Time ◽  
Synergistic Effects ◽  
Chinese Patients ◽  
Newly Diagnosed ◽  
Transducer Array ◽  
Nccn Guidelines ◽  
Tumor Treating Fields ◽  
Cutaneous Adverse Reactions

Abstract OBJECTIVES Tumor Treating Fields (TTFields) has been shown to improve the overall survival of newly diagnosed GBM (ndGBM) when combined with Temozolomide (TMZ) in the EF-14 trial. Preclinical studies suggested synergistic effects between TTFields and radiotherapy. This study is aimed to examine the safety and efficacy of combination therapy (chemoradiation concurrent with TTFields treatment) for ndGBM patients in China. METHODS From July 2020 to May 2021, 33 ndGBM patients were treated with combination therapy (radiation target volume following NCCN guidelines). Eight patients had transducer array removed during radiotherapy, others retained transducer array on scalp. All patients had assessment every two months by MRI scan. The adverse reactions and monthly compliance data for TTFields treatment were recorded. RESULTS Twenty-five patients have completed the combination therapy. Three patients retained transducer array during radiotherapy but did not limit the scalp dose (mean: 21.7Gy). As a result, Grade 2 cutaneous adverse reactions developed, and TTFields treatment was suspended. Four patients suspended TTFields treatment due to other adverse reactions. The remaining patients who had limited scalp doses (mean < 20Gy) had no suspension or delay in combination therapy due to cutaneous adverse reactions. The median time of TTFields treatment during radiotherapy is 21.24 hours/day (IQR:19.26,22.08). Two patients had progressive disease, 1 died of pulmonary infection, and 30 had stable disease. The incidence of cutaneous AE was 48.5% (16/33), Grade1: 27.2% (9/33), Grade 2: 21.2% (7/33), and Grade 3: 3% (1/33). CONCLUSIONS The combination therapy was well tolerated in Chinese patients with ndGBM. Removing transducer array during radiotherapy may increase the frequency of array replacement while reducing the patient's daily treatment time. However, retaining transducer array will increase cutaneous adverse reactions. Scalp dose limitation is required yet it allows a maximum duration of TTFields. Further follow-ups are ongoing.

scholarly journals In VitroPharmacodynamics of Vancomycin and Cefazolin Alone and in Combination against Methicillin-Resistant Staphylococcus aureus

2011 ◽  
Vol 56 (1) ◽  
pp. 202-207 ◽  
Author(s):  
Mao Hagihara ◽  
Dora E. Wiskirchen ◽  
Joseph L. Kuti ◽  
David P. Nicolau
Keyword(s):  
Staphylococcus Aureus ◽  
Combination Therapy ◽  
Synergistic Effects ◽  
Bacterial Density ◽  
Bacterial Killing ◽  
Methicillin Resistant ◽  
Content Type ◽  
Vancomycin Mics ◽  
Time Kill

ABSTRACTPrevious studies employing time-kill methods have observed synergistic effects against methicillin-resistantStaphylococcus aureus(MRSA) when a β-lactam is combined with vancomycin. However, these time-kill studies have neglected the importance of human-simulated exposures. We evaluated the effect of human simulated exposures of vancomycin at 1 g every 8 h (q8h) in combination with cefazolin at 1 g q8h against various MRSA isolates. Four clinical isolates (two MRSA isolates [vancomycin MICs, 0.5 and 2.0 μg/ml], a heterogeneous vancomycin-intermediateS. aureus[hVISA] isolate [MIC, 2.0 μg/ml], and a vancomycin-intermediateS. aureus[VISA] isolate [MIC, 8.0 μg/ml]) were evaluated in anin vitropharmacodynamic model with a starting inoculum of 106or 108CFU/ml. Bacterial density was measured over 48 to 72 h. Time-kill curves were constructed, and the area under the bacterial killing and regrowth curve (AUBC) was calculated. During 106CFU/ml studies, combination therapy achieved greater log10CFU/ml changes than vancomycin alone at 12 h (−4.31 ± 0.58 versus −2.80 ± 0.59,P< 0.001), but not at 48 h. Combination therapy significantly reduced the AUBC from 0 to 48 h (122 ± 14) compared with vancomycin alone (148 ± 22,P= 0.017). Similar results were observed during 108CFU/ml studies, where combination therapy achieved greater log10CFU/ml changes at 12 h than vancomycin alone (−4.00 ± 0.20 versus −1.10 ± 0.04,P< 0.001) and significantly reduced the AUBC (275 ± 30 versus 429 ± 37,P< 0.001) after 72 h of incubation. In this study, the combination of vancomycin and cefazolin at human-simulated exposures improved the rate of kill against these MRSA isolates and resulted in greater overall antibacterial effect, but no differences in bacterial density were observed by the end of the experiments.

scholarly journals Carrier-free, self-assembled pure drug nanorods composed of 10-hydroxycamptothecin and chlorin e6 for combinatorial chemo-photodynamic antitumor therapy in vivo

Nanoscale ◽  
2017 ◽  
Vol 9 (38) ◽  
pp. 14347-14356 ◽  
Author(s):  
Yan Wen ◽  
Wei Zhang ◽  
Ningqiang Gong ◽  
Yi-Feng Wang ◽  
Hong-Bo Guo ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Self Assembly ◽  
Chlorin E6 ◽  
Antitumor Therapy ◽  
Carrier Free ◽  
Pure Drug ◽  
Self Assembled

Carrier-free nanodrug HCPT/Ce6 NRs were prepared through a simple self-assembly approach for chemo-photodynamic combination therapy of tumors in vivo.

scholarly journals Combination pharmacotherapy in Alzheimer's disease

2003 ◽  
Vol 5 (3) ◽  
pp. 299-305
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Combination Therapy ◽  
Synergistic Effects ◽  
Current Therapy ◽  
Combination Drug ◽  
Term Care ◽  
Available Information ◽  
Individual Efficacy

Alzheimer's disease is a progressive, debilitating form of dementia affecting more than 18 million people worldwide. Without a cure, many patients and their families must turn to long-term care institutions during the later stages of the disease. Our current treatments only delay progression and help control behavioral symptoms. In recent years, research within this field has expanded to include many clinical trials on potential drug therapies. However, despite the numerous studies, the enigma of this disease remains. It is difficult yet necessary, to stay abreast of emerging information that may warrant changes in current therapy. Rationale for combination therapy becomes evident as we review the multiple neurochemical pathways common to the disease. This paper will review available information on Alzheimer's disease pharmacotherapy, and evaluate data on the use of combination drug therapy. Individual efficacy, possible synergistic effects, and the safety of combination therapy will also be addressed.

Synergistic effects of an innovative combination therapy on treating Alzheimer's disease involving modulation of gut dysbiosis

2020 ◽  
Vol 16 (S9) ◽  
Author(s):  
Feng‐Shiun Shie ◽  
Chia‐Yu Hsu ◽  
Po‐Kuan Chao ◽  
Jung‐Tsung Hsueh ◽  
John Tsu‐An Hsu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Combination Therapy ◽  
Synergistic Effects ◽  
Gut Dysbiosis
Sign in / Sign up

Export Citation Format

Share Document